# EDGAR Filing Document

**Accession Number:** 0001715925
**File Stem:** 0001062993-23-000464
**Filing Date:** 2023-1
**Character Count:** 5850
**Document Hash:** c7c726834f9a4a0bc1e0e8a34481b4ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-000464.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001062993-23-000464

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221213

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImmunoPrecise Antibodies Ltd.
- **CENTRAL INDEX KEY:** 0001715925
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39530
- **FILM NUMBER:** 23510837

**BUSINESS ADDRESS:**
- **STREET 1:** 880 - 580 HORNBY STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C3B6
- **BUSINESS PHONE:** 6048060626

**MAIL ADDRESS:**
- **STREET 1:** 880 - 580 HORNBY STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C3B6

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**<br>**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of <u>**January, 2023.**</u>

Commission File Number: <u>**001-39530**</u>

<br><u>**ImmunoPrecise Antibodies Ltd.**</u><br>(Exact Name of Registrant as Specified in Charter)<br><u>**3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8**</u><br>(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **IMMUNOPRECISE ANTIBODIES LTD.** | **IMMUNOPRECISE ANTIBODIES LTD.** |
| Date: | January 5, 2023 | By: | */s/ Brad McConn* |
|  |  | Name: | Brad McConn |
|  |  | Title: | Chief Financial Officer |

---

------

<u>**EXHIBIT INDEX**</u>

[99.1](exhibit99-1.htm) [Report of Voting Results](exhibit99-1.htm)

------

## Exhibit 99.1

------

**Report of Voting Results<br>Submitted Pursuant to**

**Section 11.3 of National Instrument 51-102 - *Continuous Disclosure Obligations***

In accordance with Section 11.3 of National Instrument 51-102 - *Continuous Disclosure Obligations*, this report describes the matters voted upon and the outcome of the votes at the annual general and special meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "**Company**") held on December 13, 2022, at the offices of Lavery, de Billy, L.L.P., 1 Place Ville Marie, 40<sup>th</sup> Floor, Montreal, Quebec (the "**Meeting**"). Each of the matters is described in greater detail in the Company's management information circular dated November 11, 2022 (the "**Circular**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The number of directors was set at six. The following are the voting results on this matter:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FOR** | **% FOR** | **AGAINST** | **% AGAINST** |
| **Number of Directors** | 4172534 | 96.16% | 166745 | 3.84% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the Circular, management of the Company proposed six nominees for election as directors of the Company for the ensuing year or until their successors are duly elected or appointed. After distribution of the Circular and proxy materials, Anna K. Petterson, a nominee for re-election, notified the Company that she has accepted a position with another company and, due to a potential conflict of interest, will no longer be acting as a director of the Company. The remaining five nominees were elected. The following are the voting results on this matter:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FOR** | **% FOR** | **WITHHELD** | **% WITHHELD** |
| **Jennifer L. Bath** | 4277141 | 98.57% | 62138 | 1.43% |
| **Robert D. Burke** | 3891345 | 89.68% | 447934 | 10.32% |
| **Lisa Helbing** | 4148499 | 95.60% | 190780 | 4.40% |
| **James Kuo** | 1664677 | 38.36% | 2674602 | 61.64% |
| **Gregory S. Smith** | 3733816 | 86.05% | 605463 | 13.95% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Grant Thornton LLP was reappointed as the Company's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **FOR** | **% FOR** | **WITHHELD** | **% WITHHELD** |
| **Reappointment of Auditors** | 6210748 | 99.84% | 9784 | 0.16% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company's 10% rolling stock option plan was approved and ratified. The following are the voting results on this matter:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **FOR** | **% FOR** | **AGAINST** | **% AGAINST** |
| **Stock Option Plan** | 4273041 | 98.47% | 66238 | 1.53% |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company's shareholder rights plan was reconfirmed. The following are the voting results on this matter:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FOR** | **% FOR** | **AGAINST** | **% AGAINST** |
| **Shareholder Rights Plan** | 4297459 | 99.04% | 41820 | 0.96% |

---

Dated this 5<sup>th</sup> day of January 2023.

---

| | |
|:---|:---|
| **IMMUNOPRECISE ANTIBODIES LTD.** | **IMMUNOPRECISE ANTIBODIES LTD.** |
| **By:** | **(signed) Brad McConn** |
|  | **Name: Brad McConn** |
|  | **Title: Chief Financial Officer** |

---

------